Labelling and packaging
The regulation of medicines and medical devices extends to how they are labelled and packaged. The rules can be complex, depending on the product.
Latest alerts
-
Takeda Pharmaceuticals Australia has issued a product alert for Vyvanse capsules due to minor packaging errors. The medication is safe to use as prescribed.
-
If you've purchased APOHEALTH Paracetamol Pain Relief paracetamol 500 mg film-coated tablets in a bottle, ensure it is kept out of reach of children. This product does not have child-resistant packaging.
-
Recall of JSHealth Vitamins listed medicine Detox + Debloat.
Latest articles
-
What do I need to do if my medicine or medical device is recalled?
Like all goods available in Australia, therapeutic goods can sometimes experience problems. When this happens, we decide if a ‘market action’ is needed. A market action aims to correct the problem. There are four types of market actions you should be aware of. -
More medicines begin transition to sole ingredient names soon
The dual labelling period for some medicine ingredients is ending on 30 April 2025. -
Updates to requirements and guidance for labels of injectable medicines
Find out about new requirements for labels of injectable electrolyte medicines and updates to guidance for medicine sponsors.
Latest publications
-
Regulation impact statement: General requirements for labels for medicines